InvestSMART

Memphasys Limited (ASX:MEM)

ALERT: Price-sensitive ASX Announcement for MEM
Current share price for MEM : $0.005 -0.002 (-28.57%)+
Announcement
Release
5 Aug 2026 8:44AM
Price at Release
$0.007
Full Release
download
Summary
Memphasys Limited has entered an exclusive commercialisation agreement with TK Biotech Sp. z o.o. for the sale and commercialisation of the Felix™ System in Poland, marking a significant step in its European commercial roll-out. The agreement, valued at approximately A$350,000 over two years, includes a three-month evaluation period followed by regular quarterly orders. This move is supported by Poland's expanding IVF sector due to public funding programs. The partnership with TK Biotech is expected to leverage their established IVF presence and technical capability to introduce Felix™ across the Polish market.
Key Points
  • Memphasys enters into a A$350,000 agreement with TK Biotech in Poland.
  • The agreement includes an initial evaluation period and a two-year commercial term.
  • TK Biotech appointed as the exclusive commercialisation partner for Felix™ in Poland.
  • Poland is the third European market for Felix™ after Italy and the UK.
  • The deal capitalizes on Poland's growing publicly funded IVF program.
  • Memphasys aims to convert European interest into contracted partnerships and revenue.
  • The agreement reflects Memphasys' strategy to build recurring sales through local partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.